Establishment, characterization, and drug sensitivity of a new Ewing sarcoma cell line (SS-ES-1).
Ewing sarcoma (ES) is one of the most malignant tumors in children and young adults. We present here a new ES cell line, SS-ES-1, established from the left thoracic tumor of a 16-year-old female patient. The SS-ES-1 cells retained genotype, morphology, and growth rate for over 150 passages. Immunocytochemical staining showed the strong immunoreactivity for cytokeratin, epithelial membrane antigen, neurofilament, CD99, P53, Ki-67, platelet-derived growth factor receptor-β, estrogen receptor-α (ER-α), and Bcl-2, but no reactivity for glial fibrillary acidic protein, epidermal growth factor receptor, and HER-2/neu. The presence of the type 1 EWS/FLI-1 fusion transcripts was confirmed by reverse transcriptase-polymerase chain reaction. On the basis of the MTT assay results, GW2974, a dual inhibitor of epidermal growth factor receptor and HER-2/neu, exhibited only a weak cytotoxic response in SS-ES-1 cells. In contrast, tyrphostin A9, a specific inhibitor of platelet-derived growth factor receptor, had a high cytotoxic effect against these cells. Surprisingly, it was found that SS-ES-1 cells displayed a high sensitivity to 4OH-tamoxifen. In conclusion, the SS-ES-1 cell line shows unique cellular properties, which makes it a useful model for studying various aspects of the biology of ES. In addition, the results suggest that ER can be a good therapeutic target for ER + ES.
Kerman Neuroscience Research Center, Medical Science University of Kerman, Kerman, Iran. Srajabalian@yahoo.com
Saeed
S
Rajabalian
Zahra
Z
Hajializadeh
Iran
I
Pooraboli
Hamid
H
Jangi-Aghdam
Marziyeh
M
Badinloo
D000293:Adolescent; D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000378:metabolism; D018929:Cell Culture Techniques / Q000379:methods; D002455:Cell Division / Q000502:physiology; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D009363:Neoplasm Proteins / Q000378:metabolism; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D051789:Proto-Oncogene Protein c-fli-1 / Q000235:genetics; D011799:Quinazolines / Q000494:pharmacology; D034802:RNA-Binding Protein EWS; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D013629:Tamoxifen / Q000494:pharmacology*; D020032:Tyrphostins / Q000494:pharmacology
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C106031:EWS-FLI fusion protein; C506645:GW2974; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D051789:Proto-Oncogene Protein c-fli-1; D011799:Quinazolines; D034802:RNA-Binding Protein EWS; D020032:Tyrphostins; D013629:Tamoxifen; C406122:tyrphostin A9